Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TL-925 by Telios Pharma for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval
TL-925 is under clinical development by Telios Pharma and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to...
Data Insights
TL-925 by Telios Pharma for Allergic Conjunctivitis: Likelihood of Approval
TL-925 is under clinical development by Telios Pharma and currently in Phase II for Allergic Conjunctivitis. According to GlobalData, Phase...